10-Q: Surmodics Reports Q1 2024 Results: Revenue Growth Driven by Medical Device Sales

Surmodics' first quarter of fiscal year 2024 saw a 23% increase in revenue, primarily driven by strong performance in the Medical Device segment.

Summary

• Surmodics reported a 23% increase in total revenue for the first quarter of fiscal year 2024, reaching $30.6 million, compared to $24.9 million in the same period last year.
• The Medical Device segment experienced a 24% revenue increase, driven by a 43% rise in product sales, including the initial stocking order for the SurVeil drug-coated balloon (DCB) from Abbott and growth in Pounce thrombectomy device sales.
• In Vitro Diagnostics (IVD) revenue grew by 18%, with product sales increasing by 17% due to strong customer demand for antigen and microarray products.
• Product gross profit increased by 12%, but product gross margin decreased to 53.2% from 63.0% due to a shift in revenue mix towards lower-margin medical devices and under-absorption of fixed costs.
• Research and development (R&D) expenses decreased by 32% due to lower SurVeil DCB R&D costs and the impact of a spending reduction plan, while selling, general, and administrative (SG&A) expenses decreased by 5% due to lower headcount.
• The company reported a net loss of $0.8 million, an improvement from a net loss of $7.8 million in the same quarter of the previous year.
• Cash used in operating activities was $8.8 million, compared to $10.8 million in the prior year, with changes in operating assets and liabilities impacting cash flow.
• The company's cash and cash equivalents and available-for-sale investments totaled $35.2 million as of December 31, 2023, a decrease of $10.2 million from September 30, 2023.

Sentiment

Score: 7

Explanation: The document shows positive revenue growth and improved profitability, but also highlights challenges with gross margins and cash flow. The company is making progress but faces risks and uncertainties.

Positives

• The company experienced significant revenue growth of 23% year-over-year.
• Medical Device product sales saw a substantial increase of 43%, indicating strong market demand for their products.
• The commercial launch of the SurVeil DCB in the U.S. is a major milestone.
• R&D and SG&A expenses decreased, reflecting cost management efforts.
• The company has access to a revolving credit facility and term loans, providing financial flexibility.
• The net loss improved significantly compared to the same quarter last year.

Negatives

• Product gross margin decreased from 63.0% to 53.2%, primarily due to a shift in revenue mix towards lower-margin medical devices.
• The company experienced a net loss of $0.8 million for the quarter.
• Cash used in operating activities was $8.8 million, indicating a need for improved cash flow management.
• Cash and cash equivalents and available-for-sale investments decreased by $10.2 million during the quarter.

Risks

• The company's reliance on a small number of significant customers, including Abbott and Medtronic, poses a risk to revenue stability.
• The company faces challenges in successfully manufacturing the SurVeil DCB at commercial volumes.
• The company's ability to successfully commercialize its vascular intervention products through its direct salesforce is uncertain.
• The company's ability to comply with the terms of its secured credit facility and term loan facilities is critical.
• The company faces risks associated with new product development and regulatory approval processes.
• The company's operating expenses related to new technologies and products may not be effective.
• The company may experience impairment of goodwill and intangible assets.
• The company's plan to reduce cash usage may not achieve its objectives.
• The company is exposed to interest rate risk on its floating rate debt.
• The company is exposed to currency risk with respect to its manufacturing operations in Ireland and sales to Abbott.

Future Outlook

The company expects R&D expenses to decrease by $5.5 to $6.5 million for the full fiscal year 2024 compared to 2023, while SG&A expenses are expected to increase by $2.0 to $3.0 million. The company believes its existing cash, investments, and credit facilities will be sufficient to meet its cash needs for fiscal 2024. The company's long-term cash requirements will depend on the market acceptance of its medical device products and future corporate transactions.

Management Comments

• The company's strategy of developing its own medical device products has increased, and will continue to increase, its relevance in the medical device industry.
• The company believes that the ease of use, intuitive design and efficient performance of its thrombectomy products make these devices viable first-line treatment options for interventionalists.

Industry Context

The medical device industry is characterized by innovation and regulatory hurdles. Surmodics' focus on vascular intervention devices and performance coating technologies aligns with the industry's trend towards minimally invasive procedures and advanced materials. The company's partnership with Abbott for the SurVeil DCB is a common strategy in the industry to leverage established distribution networks. The company's direct sales strategy for its thrombectomy and radial access platforms is a more aggressive approach to capture market share.

Comparison to Industry Standards

• Surmodics' revenue growth of 23% is strong compared to the average growth rate of the medical device industry, which is typically in the single-digit range.
• The company's product gross margin of 53.2% is lower than some of its competitors in the medical device space, which often have margins above 60%. Companies like Medtronic and Boston Scientific typically have higher gross margins due to their scale and established product portfolios.
• Surmodics' R&D spending as a percentage of revenue is decreasing, which is a trend seen in companies transitioning from development to commercialization. However, companies like Edwards Lifesciences and Abbott continue to invest heavily in R&D to maintain their competitive edge.
• The company's reliance on a few key customers is a common risk in the medical device industry, where large distributors and group purchasing organizations have significant influence. Companies like Stryker and Johnson & Johnson have diversified customer bases to mitigate this risk.
• The company's debt levels are moderate compared to some of its peers, but the interest rate swap arrangement provides some protection against rising interest rates. Companies like Zimmer Biomet have higher debt levels due to acquisitions and strategic investments.

Stakeholder Impact

• Shareholders will be impacted by the company's revenue growth and improved profitability, but also by the decrease in gross margins and cash flow.
• Employees may be impacted by the company's cost management efforts, including headcount reductions.
• Customers will benefit from the company's new product launches and expanded product offerings.
• Suppliers may be impacted by the company's production volumes and purchasing decisions.
• Creditors will be impacted by the company's debt levels and ability to meet its obligations.

Next Steps

• The company will continue to advance the commercialization of its Pounce thrombectomy and Sublime radial access product platforms.
• The company will continue to evaluate its strategy for further clinical investment in the Sundance DCB.
• The company will continue to monitor and manage its cash flow and working capital.
• The company will continue to monitor and manage its debt obligations and interest rate exposure.

Key Dates

Keywords

Medical Devices, Drug-Coated Balloon, Thrombectomy, In Vitro Diagnostics, Revenue Growth, Product Sales, R&D Expenses, Gross Margin, Commercialization, Financial Results